High-dose intravenous Vitamin C (IVC) is one of the most researched complementary therapies in oncology. While not a standalone cancer treatment, mounting evidence supports its role as an adjunctive therapy that can improve quality of life, reduce chemotherapy side effects, and potentially enhance treatment outcomes. As a physician, I believe in evidence-based medicine — so let's examine what the science actually says.
A Brief History
The therapeutic use of high-dose Vitamin C was pioneered by Dr. Linus Pauling (two-time Nobel laureate) and Dr. Ewan Cameron in the 1970s. Their work was later advanced by Dr. Hugh Riordan and the Riordan Clinic, which developed the specific IVC protocol now used by integrative practitioners worldwide. The Riordan protocol has been refined through decades of clinical experience and published research.
How It Works: The Pro-Oxidant Mechanism
At low oral doses, Vitamin C acts as an antioxidant — protecting cells from free radical damage. But at the supraphysiological concentrations achievable only through IV administration (plasma levels of 350-400 mg/dL), Vitamin C undergoes a remarkable transformation: it becomes a pro-oxidant.
At these concentrations, Vitamin C generates hydrogen peroxide (H2O2) in the extracellular fluid surrounding tissues. Normal, healthy cells contain the enzyme catalase, which rapidly breaks down H2O2 into water and oxygen — rendering it harmless. Cancer cells, however, are typically catalase-deficient, making them vulnerable to H2O2-mediated oxidative damage.
In essence, high-dose IVC selectively targets cancer cells while leaving healthy cells unharmed — a selectivity that most conventional chemotherapy agents cannot achieve.
The Riordan Protocol at Zen
Our IVC protocol follows the Riordan guidelines with physician oversight at every step:
- Pre-treatment screening: G6PD enzyme test (required to rule out G6PD deficiency), comprehensive metabolic panel, and renal function assessment
- Graduated dosing: Starting at 15-25g and titrating up to 50-75g based on patient response and lab values
- Infusion time: 60-120 minutes depending on dose, administered in our private infusion suites
- Frequency: 2-3 times per week during active treatment phases, transitioning to weekly maintenance
- Monitoring: Regular lab work including Vitamin C plasma levels, kidney function, and electrolytes
What the Research Shows
A 2018 study published in Cancer Cell demonstrated that high-dose IVC enhanced the efficacy of radiation therapy in pancreatic cancer patients while reducing side effects. Multiple Phase I/II clinical trials have confirmed safety and tolerability. Patients consistently report improved energy, reduced nausea, better appetite, and enhanced quality of life during conventional cancer treatment.
It's important to note: IVC is not a replacement for conventional oncology care. It is a complementary therapy best administered in coordination with your oncologist. At Zen, we maintain open communication with each patient's oncology team.
